Spyre Therapeutics, Inc. (SYRE)
NASDAQ: SYRE · Real-Time Price · USD
88.98
+1.73 (1.98%)
Sep 4, 2026, 4:00 PM EDT - Market closed
Spyre Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| - | - | - | 0.89 | 2.33 | 18.74 | |
Revenue Growth | - | - | - | -61.96% | -87.57% | - |
Cost of Revenue | 215.8 | 171.65 | 162.79 | 84.05 | 58.58 | 57.07 |
Gross Profit | -215.8 | -171.65 | -162.79 | -83.16 | -56.25 | -38.33 |
Selling, General & Admin | 55.54 | 47.91 | 45.78 | 34.45 | 28.53 | 27.32 |
Operating Expenses | 55.54 | 47.91 | 45.78 | 34.45 | 28.53 | 27.32 |
Operating Income | -271.34 | -219.56 | -208.57 | -117.61 | -84.78 | -65.65 |
Interest & Investment Income | 29.57 | 24.89 | 21.31 | 6.15 | 0.84 | 0.11 |
Other Non Operating Income (Expenses) | -7.14 | 29.46 | -20.71 | -102.66 | -0.01 | -0.12 |
EBT Excluding Unusual Items | -248.92 | -165.22 | -207.97 | -214.13 | -83.95 | -65.66 |
Merger & Restructuring Charges | - | - | - | -10.95 | - | - |
Gain (Loss) on Sale of Assets | 70 | 10 | - | 16.45 | - | - |
Pretax Income | -178.92 | -155.22 | -207.97 | -338.82 | -83.95 | -65.66 |
Income Tax Expense | - | -0.02 | 0.05 | -0.03 | -0.14 | 0.14 |
Net Income | -178.92 | -155.2 | -208.02 | -338.79 | -83.82 | -65.8 |
Preferred Dividends & Other Adjustments | -28.71 | -28.66 | -58.46 | -243.91 | - | - |
Net Income to Common | -150.21 | -126.54 | -149.56 | -94.88 | -83.82 | -65.8 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 75 | 64 | 47 | 7 | 3 | 3 |
Shares Outstanding (Diluted) | 75 | 64 | 47 | 7 | 3 | 3 |
Shares Change | 31.80% | 36.21% | 581.85% | 104.59% | 28.19% | 23.18% |
EPS (Basic) | -2.01 | -1.98 | -3.18 | -13.76 | -24.86 | -25.02 |
EPS (Diluted) | -2.01 | -1.98 | -3.18 | -13.76 | -24.86 | -25.02 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -208.94 | -169.25 | -157.41 | -99.91 | -80.18 | -54.29 |
Free Cash Flow Per Share | -2.80 | -2.64 | -3.35 | -14.49 | -23.78 | -20.64 |
Gross Margin | - | - | - | - | - | -204.55% |
Operating Margin | - | - | - | -13274.49% | -3640.23% | -350.33% |
Profit Margin | - | - | - | -10709.14% | -3598.76% | -351.14% |
Free Cash Flow Margin | - | - | - | -11276.52% | -3442.76% | -289.71% |
EBITDA | - | - | -207.82 | -116.87 | -83.21 | -64.07 |
D&A For EBITDA | - | - | 0.74 | 0.74 | 1.57 | 1.58 |
EBIT | -271.34 | -219.56 | -208.57 | -117.61 | -84.78 | -65.65 |
Revenue as Reported | - | - | - | 0.89 | 2.33 | 18.74 |